Biotech of the week: Mologen, the Largest Publicly-listed Biotech of Berlin

16/10/2015 - 2 minutes

This week, we’re leaving Paris and heading East to a city that’s 9 times bigger than the capital of France, it’s also the city we all call home here at Labiotech, Berlin. When someone thinks of Berlin, they think of the wall, the Fernsehturm (television tower) and its amazing nightlife (I can personally agree with this 😉 ).  However, it is also famous for its biotech industry, including our biotech of the week, Mologen, one of the leading biotech companies in the fields of cell-based therapies and DNA medicine.


City: Berlin, Germany

Founded: 1998

Public Value: €90M (on 15/10/2015)

Employees: >50 (as of 10/2015) 

Mission: Mologen AG is a publicly listed company and was one of the first biotech companies in Germany to be listed on the stock exchange shortly after its founding. It specializes in research and clinical development of drugs focused on oncology and infectious diseases. They currently have 2 platform technologies which allow a patient’s immune system to fight the disease or pathogen itself,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!